Osivax Flu Vaccine Trial

The research project is testing a potential new vaccine to prevent influenza (flu). The potential new vaccine is called OVX836. In this study OVX836 will be administered alongside an already approved and marketed flu vaccine, Vaxigrip Tetra® (QIV Brand 1) and Afluria Tetra® (QIV Brand 2), that is designed to protect against 4 different flu viruses (quadrivalent flu vaccine). You may also be randomised to receive a placebo vaccine.

Trial Status
Trial Phase
Phase 2 Drug Trial
Registry Listing
ERM Project ID
Trial contact details
Contact Person
RIO Clinical Trials Unit
What you need to know

Who can take part?

You may participate in the study if you:

  • Are between 18 and 60 years of age
  • Have received at least two doses of a licensed severe acute respiratory syndrome Coronavirus 2 vaccine
  • Able to read, understand and complete an electronic diary and electronic patient reported outcome questionnaire


You may not participate in the study if you:

  • Are pregnant or breastfeeding
  • Previous influenza vaccination within 6 months before the day of vaccination or planned to receive influenza vaccination during the whole study period.
  • Past (stopped less than 6 months before enrolment) or current smoking habit above 10 cigarettes per day

Certain pre-existing conditions and medications may make you unable to participate.  The study doctor will discuss these with you if you are interested in participating.

People who are able to have children must agree to avoid becoming pregnant or fathering a child while participating in the study.


What is involved for you?

Participants in the study will undertake the following assessments, tests and procedures:

  • Medical history (Including Vaccination History)
  • Physical exam
  • Blood tests
  • Pregnancy test (women who can have children only)
  • 2 Injections of Vaccinations (one in right upper arm and one in the left upper arm)
  • Complete electronic diary everyday for 7 days post Vaccine
  • If you develop Flu like symptoms during the trial period (6 months) you will complete a diary questionnaire and perform a nasal self-swab

All research clinical trials news

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...



Stephanie Guilas is improving outcomes for mums and bubs through research

Working as a research assistant in an immunology research lab, Yvonne Gautam learnt what a clinical trial was after being asked to set up a lab for a Phase Two clinical trial.



Clinical Trials Coordinator Yvonne Gautam is working towards creating better treatments for patients with diabetes

Displaying results 1-3 (of 16)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|